Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 Study of CX-2009 Alone and with CX-072 in Advanced Breast Cancer (CTMX-2009-002)
2020-004618-36Phase 2Completed
- Sponsor
- CytomX Therapeutics, Inc.
- Start
- Feb 2021
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of praluzatamab ravtansine and pacmilimab in breast cancer and triple-negative breast cancer (TNBC) (3 arms), sponsored by CytomX Therapeutics, Inc. Primary endpoint: Primary endpoint (CX-2009 Monotherapy Arms A and B). Started Feb 2021; status: completed.
02
Drugs
praluzatamab ravtansinepacmilimab
03
Conditions
breast cancertriple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on 2020-004618-36.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-004618-36.